Important note: Information in this article was accurate in 2005. The state of the art may have changed since the publication date.
Agence France Presse (12.07.05) - Wednesday, December 07, 2005
Jerome Cartillier
In Africa, the continent most-affected by HIV/AIDS, the gap is even wider, with just half a million or "at best one person out of 10" in need of ARVs actually receiving them by mid- 2005, according to UNAIDS.
However, experts said, the initiative begun in 2003 is a promising development for treating the world's poorest HIV/AIDS patients in the future. "We've said for a long time that we're not going to meet 3 by 5," said Jim Yong Kim, WHO's head of HIV/AIDS. "But on the other hand we're extremely excited about what happened after 3 by 5," he said, adding that "we have learned a basic lesson that businesses have known for a long time, the importance of setting a concrete target in a timeframe."
"I think [3 by 5] gave the momentum," said Doctors Without Borders' South Africa Head of Mission Eric Goemaere. "We needed a quantitative objective. It was the best and only way to get people to work on these issues." "I have never seen a sophisticated program like the ARV program kick-start so rapidly," he said. "I don't think there is any precedent in history." Even so, Goemaere noted, the tiny number of patients receiving ARVs "remains a scandal from a moral point of view."
"It's normal it should get off to a slow start, a lot of obstacles have to be overcome," said Donald de Korte, an executive for the US-based drug firm Merck. "You see the same phenomenon across the board in all countries: ARV distribution follows an exponential curve," he said. "I think it's reasonable to suppose that the next 500,000 will be reached by the end of 2006."
051207
AD052464
Copyright © 2005 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
.